



Annual General Meeting BioNTech SE

May 25, 2023

English Convenience Translation: German is the official language.

Slide 1: Annual General Meeting of BioNTech SE

Slide 2: Report of the Management Board on Agenda Item 1

Prof. Ugur Sahin, M.D., CEO & Co-Founder

Slide 3: OPERATIONS DEVELOPMENT 2022 & Q1 2023 AND OPERATIONS OUTLOOK

Ladies and Gentlemen, shareholders and shareholder representatives,

On behalf of my colleagues on the Management Board, I would like to welcome you to the Annual General Meeting of BioNTech.

Slide 4: Forward-looking Statements

Before we begin our report, please be advised that we will be making “forward-looking statements” in this Annual General Meeting.

As described on slide 4 of the presentation, these statements are subject to the risks and uncertainties detailed in our filings with the U.S. SEC, including our most recent Annual Report on Form 20-F. These statements, including without limitation those relating to our COVID-19 vaccine revenues, as these include figures that are derived from preliminary estimates provided by our partners; our estimated financial results for 2023; the continued global demand for our COVID-19 vaccine; and the planned next steps in our pipeline programs.

Actual results may differ materially from those projected in these statements. All information in this presentation is current as of the date of its preparation and BioNTech assumes no obligation to update such information.

Slide 5: Safety Information

Slide 6: Safety Information

Please also note that the following two slides provide important indication and safety information regarding our COVID-19 vaccine.



Slide 7: OUR VISION

Let me begin by saying a few introductory words.

I would like to take the opportunity and give my sincere thanks to all my colleagues, BioNTech's collaboration partners and the scientific community that worked so diligently and tirelessly and rose to meet the challenge of a pandemic and provide life-saving vaccines to the world.

In 2022, our vaccine was instrumental in preventing millions of serious illnesses and deaths worldwide and has had a significant positive impact on the global economy. A publication from The Lancet in September 2022, estimated that 19.8 million deaths were averted in 185 countries and territories, with a 63% reduction in total deaths during the first year of COVID-19 vaccinations, between December 2020 and December 2021. A recent study by the World Health Organization and the European Center for Disease Prevention and Control, published in April 2023, highlighted that vaccination prevented over 500,000 deaths in the European region during the Omicron wave alone. Our vaccine has made a significant contribution to this.

We are on our way back to a kind of new normal. Although the pandemic is currently considered to be under control, the SARS-CoV-2 virus will likely be present for years and constantly develop new variants. Our approach involves adapting our vaccines to seasonal variants and continuously monitoring potentially threatening new variants worldwide. With the technologies and innovation for pandemic preparedness that we have developed together with our partners over the past two and a half years, we are able to respond rapidly to new pandemic SARS-CoV-2 variants, beyond seasonal vaccine adaptation.

Based on this success, we are looking to the future. Our goal is to sustainably growing BioNTech and develop it into a 21st century global biopharmaceutical company. We want to address medical challenges in areas such as cancer, infectious diseases, and autoimmune and degenerative diseases. We are pursuing a clear strategy to achieve this goal. It includes accelerating our research and development activities in oncology and infectious diseases, licensing clinical compounds that complement our own products, and using our innovative technologies to develop therapies that open the door to additional therapeutic areas. Our aim is to position ourselves at the forefront of medical progress and to address the medical needs of patients around the world.

Slide 8: BioNTech Today

- We celebrate our 15-year anniversary this year, having accomplished much in a short period of time. Since our IPO in 2019, our pipeline has nearly quadrupled. We have already published positive data on many of the pipeline programs and plan to start additional trials with registrational potential in the short and medium term.
- We are well on our way to becoming a leading global biotechnology company with:
 - a global organization spanning five continents: Europe, North America, Africa, Asia and Australia;
 - a drug development engine geared towards new technologies;
 - an extensive pipeline of highly innovative product candidates;

BIONTECH

- diversified capabilities in manufacturing mRNA therapeutics and cell therapies;
- excellent, innovative collaboration partners;
- a strong balance sheet;
- and a strong, long-term orientated shareholder base.

Slide 9: Vision: A Global Next-Generation Immunotherapy Company

- Our company is based on the vision of harnessing the complex mechanisms of the immune system to fight human diseases. Our goal of building a leading global biotechnology company is driven by several factors:
 1. *“Our leading role in COVID-19 vaccine development”;*
 2. *“Our innovative and diversified pipeline”;*
 3. *“Our responsibility for healthcare internationally”:* We aim to democratize access to our innovations around the globe;” and
 4. *“Building the future-orientated structure of our organization and establishing internal frameworks to enable sustainable growth.”*

Slide 10: Advancing Towards our Vision

- On slide 10, I would like to look at our progress in 2022 in light of our long-term vision.
- Including our new collaborations, BioNTech currently has 20 programs in oncology and 7 programs in infectious diseases.
- In 2022 and the first months of 2023, we initiated four studies in oncology and five in infectious diseases.
- We plan to start several potentially registrational trials in the coming years, which should afford us the opportunity to bring additional products to the market.
- With our medicines, we want to make individualized cancer therapies available and address diseases with high medical need worldwide.

Slide 11: BioNTech Achievements in 2022 & 2023

- What have we achieved in 2022 and early 2023?
 - Together with Pfizer, we tested, successfully gained approval for and commercialized our first variant-adapted vaccine against COVID-19;
 - We are advancing our oncology pipeline towards late-stage clinical development. Today we have six ongoing Phase 2 clinical programs in oncology.
 - In infectious diseases, we launched 5 new first-in-human trials, including the world's first mRNA vaccine clinical trials for the prevention of malaria as well as tuberculosis.
 - We have increased our R&D investments and announced the strategic acquisition of InstaDeep, a leading artificial intelligence (AI) and machine learning company. This transaction gives us access to top scientists and industry-leading AI capabilities. We are thus strengthening our capabilities in AI-supported drug research.



- We have acquired several new, complementary and synergistic programs and technologies through licensing agreements and collaborations, and have entered into partnerships with, among others, DualityBio and OncoC4.
- And we've expanded our manufacturing and collaboration footprint globally, establishing mRNA manufacturing capabilities in Asia and Africa and initiating new collaborations in multiple regions and markets worldwide.

Slide 12: 2022 & 2023: Global Growth

- We built a diverse team of 4,500 people to enable strong execution on our strategic priorities.
- We have a global collaboration network with governments and organizations spanning 5 continents to ensure that potential vaccine and drug development breakthroughs can reach the international community.
 - One milestone is the strategic collaboration with the government of the United Kingdom, that aims to make personalized cancer medicine available to up to 10,000 patients in clinical trials or as approved medicines by the end of 2030.
 - The collaboration with Israel and planned partnerships with others pursue similar objectives.
 - With the acquisition of a GMP manufacturing site in Singapore, we have expanded our global footprint in a strategically important hub.
 - By creating regional manufacturing capacity, in Australia and elsewhere, we are supporting our growing pipeline of mRNA-based vaccines and therapeutics across the Asia Pacific region for both clinical and commercial scale.

Slide 13: Global Social Responsibility at Our Core

- At BioNTech we have a robust global social responsibility strategy. Core of our ambition is to enable global access to innovative medicines at an early stage. We want to achieve this goal in a sustainable way.
 1. To do so, we integrate sustainability step by step into our business processes. In this way, we are fulfilling our human rights due diligence obligations and preparing for the dynamic regulatory environment in the area of sustainability. In climate protection, we completed our climate risk analysis in 2022. We have set specific climate protection goals and are aiming for an absolute reduction in our greenhouse gas emissions by 42% by 2030 compared to the base year 2021. This goal as well as our climate protection goal for our value chain are currently being independently validated.
 2. We are committed to developing new medicines for diseases with high unmet medical needs. This starts with COVID-19 and cancer, but also includes our vaccine development programs aimed for HSV-2, tuberculosis, malaria and shingles.
 3. We want to play a role in helping to close gaps in medical care worldwide. This includes deploying modular, scalable mRNA manufacturing facilities in regions where our medicines may be most needed. To this end, we have developed the BioNTainer, a modular, turnkey



mRNA manufacturing facility based on shipping containers. The containers are built as clean rooms and are designed and equipped for mRNA production. Our BioNTainers can be transported worldwide by truck, ship or plane, making it possible to manufacture mRNA vaccines locally according to the needs of each partner country. The first planned BioNTainer location is in Kigali, Rwanda. In March 2023, six ISO-sized shipping containers for the first BioNTainer were flown to our location in Kigali. Installation will be at the end of this year. The corresponding hall for installation is currently being built.

Slide 14: 2022: COVID-19 VACCINE GLOBAL LEADERSHIP

- Let's now return in more detail to our progress and achievements in 2022, starting with our COVID-19 vaccine.

Slide 15: 2022: Continued Leadership Against COVID-19

- Last year, we and our partner Pfizer continued our global leadership in the fight against COVID-19:
 - We achieved our supply target for the year with approximately 2 billion doses invoiced.
 - The focus was on the successful global launch of our first variant adapted vaccines, with only approximately 2 months from regulatory recommendations to vaccine delivery.
 - Over the course of 2022, we shipped approximately 550 million doses of our first variant-adapted vaccine.
 - This allowed us to further strengthen the strong market position we have established for our COVID-19 vaccine franchise (with a greater than 60% market share).
 - We achieved this by further label expansion in regions around the world. Today, we offer the broadest label amongst COVID-19 vaccines.

Slide 16: COVID-19 Franchise: Building for Continued Success

- We are well positioned to sustain our scientific and commercial leadership for COVID-19 vaccines.
- One of our key accomplishments for the COVID-19 vaccine program in 2022, was the launch of the first variant-adapted vaccines.
 - Our ongoing scientific and manufacturing preparation were fundamental to the rapid execution of this launch.
- We are able to respond to new COVID-19 variants in the most efficient way.
- Powered by AI and machine learning, our early warning system and variant surveillance enables rapid development of variant-adapted vaccines.
- We are developing combination vaccines designed to protect against multiple pathogens with single-dose convenience.
- We also plan to continue developing our next-generation COVID-19 vaccine candidates throughout the year. Our own internal research suggests that T-cell recognition of current and



potentially future variants of concern may largely remain intact but should be further needs bolstered.

- With BNT162b4, we have developed a new, T-cell based vaccine candidate that is designed to address all SARS-CoV-2 variants. BNT162b4 encodes highly conserved, immunogenic segments of non-spike proteins of SARS-CoV-2 with the goal of a universal enhancement and broadening of the T-cell immune response against current and potential future variants of concern.
- Innovation remains at the core of our COVID-19 program and supports both our variant surveillance and robust clinical program.
- In 2023, we aim to develop, manufacture and deploy a seasonally adapted COVID-19 vaccine. Most recently, the World Health Organization recommended the use of a monovalent vaccine against the XBB.1 virus line, such as XBB.1.5, as the vaccine antigen. Considering the small genetic and antigenic differences, XBB.1.16 could be a suitable alternative. We are expecting a potential approval for an adapted vaccine by the end of this summer with the opportunity to start seasonal vaccinations in early fall. In addition, we aim to launch a read-to-use single-dose, and will continue to improve key Comirnaty features such as shelf stability.

Slide 17: 2022 COVID-19 Deaths and Hospitalizations Greatly Exceeded Those from Influenza in the United States

- On this slide, you will find some U.S. statistics supporting the continuing need for effective COVID-19 vaccines compared to influenza vaccines.
- Last year in the United States, there were approximately 264,000 deaths and 1.5 million hospitalizations related to COVID-19. In the same period, there were approximately 36,000 deaths and 450,000 hospitalizations due to influenza.
- According to the CDC, despite the significantly higher burden of disease, COVID-19 vaccine doses administered in the U.S. lagged those of seasonal flu, at approximately 171 million flu doses versus approximately 144 million COVID-19 vaccine doses.
- It is uncertain how these figures will change in the coming years. However, we believe that seasonal COVID-19 vaccines could gradually reach an acceptance rate similar to that of influenza vaccines over the next few years.

Slide 18: DIVERSIFIED PRODUCT PIPELINE

- In the following slides I would like to talk you through our technologies and product pipeline. Over the past year, we have significantly expanded our technology toolkit and advanced our pipeline.

Slide 19: Technology Agnostic Innovation Engine

- Our technology toolkit is one of the building blocks of our innovation strategy to drive the development of new immunotherapeutic drugs. We have built a toolkit of versatile and modular



technologies spanning 4 drug classes: mRNA vaccines and therapeutics, cell and gene therapies, protein-based therapeutics and small molecules.

- Over the last year, we added several complementary technologies to our toolkit through acquisitions and collaborations.

Slide 20: Long-Term Strategy: Expand Treatment Options for Cancer Patients

- A priority of BioNTech is to develop immunotherapies for the treatment of cancer, and we now have demonstrated clinical proof of concept in multiple new modalities.
- Our long-term oncology strategy is to expand available treatment options for cancer patients. In order to best serve the needs of cancer patients, we aim to address the full continuum of cancer treatment: We want to bring novel therapies to market for patients from adjuvant to late-stage settings.
- For many cancers, no effective therapies are available. One reason for this is that each cancer has patient-specific molecular and genetic characteristics. In addition, cancer cells are constantly changing, which is why resistance to treatment can develop over time. Our goal is to develop therapies that are individually tailored to each patient to provide a new generation of precision therapeutics for the treatment of cancer.
- Our patient-centric approach also encompasses classical biopharmaceuticals applicable to different cancer types, as well as tailored immunotherapies produced individually for each patient as needed.
- Some drug classes in our oncology pipeline are mRNA cancer vaccines, cell therapies, next-generation checkpoint immunomodulators and antibody-drug conjugates. We believe that these drug classes have the potential to drive improved outcomes for cancer patients across multiple lines of treatment and tumor types. Our most advanced oncology assets are currently in development for a range of solid tumors at all stages of treatment. We believe that these assets have first-in-class or best-in-class potential and may enable us to drive changes in the treatment of many cancers.

Slide 21: Oncology Pipeline

- On slide 21, I would like to highlight the progress of the various clinical programs in our oncology pipeline as well as our latest drug candidate additions.
- 2023 will be a year of key advancement for our mRNA cancer vaccines and we plan to initiate multiple potentially registrational trials.
- In the first quarter, we added to our clinical pipeline the following new assets:
 1. The HER2-targeting ADC DB-1303 developed by our colleagues at DualityBio, which has recently started the Phase 2 portion of the ongoing Phase 1/2 clinical trial.
 2. ONC-392: a next generation anti-CTLA-4 antibody was developed by our partner OncoC4 and is currently being tested in two ongoing clinical trials in multiple indications: in lung cancer as monotherapy and in combination with pembrolizumab in ovarian cancer.



Slide 22: Infectious Diseases: Important Growth Area Addressing High Medical and Global Health Need

- Our infectious disease research programs focus on diseases that represent both high unmet medical need and global health burdens, especially since there are no adequate treatments or vaccines available for some of these diseases.
- Today, we have ongoing clinical programs for mRNA vaccine addressing COVID-19, influenza, HSV-2, malaria, shingles and tuberculosis.
- Millions of people around the world are at risk of both infection and potential complications arising from infection.
- Despite medical advances, global morbidity from diseases such as influenza, malaria and tuberculosis remains high. Our goal is to address these problems with our innovative vaccines.

Slide 23: Infectious Disease Pipeline

Slide 23 highlights our infectious disease pipeline.

- In December of last year, we initiated the first clinical trials investigating mRNA-based vaccine for malaria and HSV prevention.
- We already started two first-in-human clinical trials testing new mRNA vaccine candidates in the first quarter of 2023: one is a vaccine against tuberculosis and the other with our partner Pfizer, is a vaccine for shingles. These programs build on our validated platform and address diseases with a significant global need.

Slide 24: OUTLOOK 2023

- Let me conclude by summarizing our strategic priorities for 2023.

Slide 25: 2023 Strategic Priorities

Our success with our COVID-19 vaccine has given us a unique opportunity to realize our long-term vision. We believe we are well positioned to take advantage of this opportunity. To this end, we are pursuing the following key priorities:

1. In collaboration with our partner Pfizer, we are striving to strengthen and expand our leadership position in COVID-19. We will achieve this by continuously advancing our vaccine candidates, developing combination vaccines and improving the product characteristics of our COVID-19 vaccine.
2. An important focus is on accelerating the development of our drug pipeline.
 - In oncology, we plan to start several potentially registrational trials.
 - In the area of infectious diseases, we also plan to further develop and expand our pipeline.
3. We continue to build our company into a global, multi-product biotechnology company addressing highly relevant medical needs worldwide.



We would like to take the opportunity to thank you, our valued shareholders. We are grateful for your continued trust and support, and it fills us with confidence as we take the next steps together in implementing our strategy and realizing our vision.

Thank you for your attention. I will now hand the meeting back to our Meeting Chairman.